{
    "symbol": "4503",
    "slug": "4503",
    "display_name": "4503",
    "category": "stocks",
    "region": "JP",
    "description": null,
    "url": "https://finscans.com/asset/4503",
    "lang": "en",
    "as_of": "2026-06-01T01:39:39+00:00",
    "stats_30d": {
        "total_signals": 1,
        "bullish": 0,
        "bearish": 1,
        "neutral": 0,
        "explicit": 1,
        "inferred": 0,
        "avg_impact": 7,
        "avg_confidence": 85,
        "last_signal_at": "2026-05-27 03:56:16",
        "article_count": 1
    },
    "top_catalysts": [
        {
            "text": "Release of a five-year strategic plan with below-consensus targets",
            "count": 1
        },
        {
            "text": "Perceived weakness in the R&D pipeline",
            "count": 1
        }
    ],
    "top_risk_factors": [
        {
            "text": "Positive clinical trial data could reverse sentiment",
            "count": 1
        },
        {
            "text": "Broader pharma sector strength lifting the stock",
            "count": 1
        }
    ],
    "recent_signals": [
        {
            "signal_at": "2026-05-27 03:56:16",
            "sentiment": "Bearish",
            "impact_score": 7,
            "confidence_score": 85,
            "mention_type": "explicit",
            "timeframe": "short-term",
            "region": "JP",
            "reasoning": "Astellas Pharma shares fell after the company released a five-year strategic plan that underwhelmed investors. The plan's conservative growth targets and lack of near-term pipeline catalysts drove a sell-off, reflecting disappointment over the company's ability to offset patent cliffs.",
            "article": {
                "title": "Astellas Pharma Stock Tumbles as Five-Year Plan Disappoints Investors",
                "url": "https://finscans.com/news/astellas-pharma-stock-tumbles-as-five-year-plan-disappoints"
            }
        }
    ]
}